The purpose of this study was to determine whether cefonicid, a cephalosporin antibiotic with a modified N-methylthiotetrazole (MTT) side chain, caused testicular toxicity when subcutaneously administered to Sprague-Dawley male rats from days 6 to 36 postpartum at doses of 50 to 1,00Q mg/kg per day. Moxalactam (a cephamycin antibiotic which will be referred to as a cephalosporin for convenience throughout), which contains the MTT side chain, was used as a positive control and was administered at 100 to 1,000 mg/kg per day, and cephalothin, which lacks an MTT side chain, was used as the negative control at 1,000 mg/kg per day. Moxalactam caused a significant reduction in testicular and seminal vesicle weights in 37-day-old animals, and histological examination revealed bilateral multifocal atrophy of the seminiferous tubules at all dose levels. Animals reared to reproductive maturity had significant deficits in fertility, and histological examination revealed multifocal or diffuse atrophy of the seminiferous tubules at all doses with a severity greater than that observed in the 37-day-old animals. The histological findings were confirmed by marked reductions in testicular sperm production rates and cauda epididymal sperm numbers. Cephalothin and cefonicid had no treatmentrelated adverse effects on the sexual maturation of prepubertal, juvenile, or adult males. The absence (in cephalothin) or modification (in cefonicid) of the MTT side chain was not associated with adverse reproductive effects. The relevance of these findings to humans in prenatal and prepubertal stages of life cannot be determined at this time.
juvenile rats (1, 14) . When administered subcutaneously to male rats from days 6 through 36 of age, cefoperazone, cefamandole, and moxalactam, as well as the MTT side chain alone, caused testicular atrophy and germ cell depletion of the seminiferous tubules. With cefamandole, these effects were observed in juvenile rats treated with as little as 50 to 100 mg/kg per day for the 30-day period (14) . No adverse effects occurred in rats treated in utero, in neonatal rats treated from birth to 4 days of age, or in rats more than 35 days old (16) .
Cephalosporin antibiotics lacking the MTT side chain (cephalothin and cefazolin) did not cause testicular atrophy when tested under identical conditions (14) . Cefonicid is a cephalosporin antibiotic with a modified MTT side chain, which is a methylsulfonic-thio-tetrazole group (Fig. 1) . Reproduction studies of cefonicid have been performed with mice, rabbits, and rats with doses up to an equivalent of 40 * Corresponding author.
times the usual adult human dose and have revealed no evidence of impaired fertility or harm to the fetus or neonate (17) . In these previous studies with cefonicid, however, the drug was administered to the dam, and exposure of the neonate occurred via lactation. The level of neonatal exposure via lactation during the critical period for the testicular effect would be considerably less than that by direct, subcutaneous treatment. The subcutaneous route of drug administration is relevant to the therapeutic use of cephalosporn antibiotics in human infants. Consequently, this study was undertaken to determine if cefonicid caused testicular toxicity when subcutaneously administered to rats from days 6 to 36 of life. Moxalactam (with MTT) and cephalothin (without MTT) were used as positive and negative antibiotic controls, respectively, and were tested under identical conditions.
(Some of the data in this manuscript were presented in a poster at the March 1986 meeting of the Society of Toxicology, New Orleans, La., and were published as study. After spontaneous deliveries, litters were culled for maintenance of six male pups per litter whose body weights were closest to the mean. Four litters, each containing a total of 24 pups, were randomly assigned to the control group or to one of nine drug-treated groups on the basis of ranked average litter weights.
Based on results from a pilot study and the recommended human pediatric dosing regimen (18) , moxalactam dosages of 100, 500, and 1,000 m.g/kg per day were selected for the present study. Cephalothin was used as an MTT-negative antibiotic control and was administered at 1,000 mg/kg per day. Cefonicid is not currently indicated for use in human infants (17) . Dose selection was based on responses observed in the pilot study with moxalactam, and cefonicid was administered at 50, 100, 250, 500, and 1,000 mg/kg per day. Drug solutions were given by subc'utaneous (flank) injection to male rat pups on days 6 to 36 postpartum (10 ml/kg on days 6 to 20 and 5 ml/kg on days 21 to 36). The site of injection was changed from the left to the right flank each day to minimize irritation. The control males received equivalent volumes of saline during the same period.
On day 37, half the males (12 per group) were killed by CO2 asphyxiation and were autopsied. The testes, epididymides, seminal vesicles, and ventral prostates were weighed and fixed for histological examination. Sera were saved for hormone analysis. The remaining males (12 per group) were reared to 102 days of age for evaluation of a variety of reproductive parameters. From days 37 to 70 of age, rats were examined for balanopreputial separation, a physical landmark for male sexual maturation. Preputial separation is an androgen-dependent index of puberty in the male rat. The separation precedes the appearance of motile sperm in the caput epididymis and coincides with the rise in circulatory androgens (12 Changes in sperm production rate can be measured by direct evaluation of testicular spermatid reserves. Since elongated spermatids are the most mature germ cell found in the seminiferous tubules, alterations in spermatogenesis at any stage should be reflected in changes in spermatid reserves once a full cycle of spermatogenesis is completed (6) . Measurement of the sperm production rate entails homogenization of the testicular parenchyma in a detergent-rich solution which destroys the nuclei of somatic cells and all other germinal cells except for elongated spermatid nuclei. Resistant spermatid nuclei are counted in a hemocytometer and values are divided by 6.10 days, the time required for spermatids to form sperm in the rat, to obtain the sperm production rate (6, 9) .
Sperm first appear in the cauda epididymis of rats at approximately 8 weeks of age (20) and retain their fertilizing capacity in the cauda for 20 to 35 days in most mammalian species (3). The number of sperm within the cauda at any time is a function of the sperm production rate of the associated testis and the rate of movement of sperm through the epididymal duct. Caudal sperm count was determined in the same manner as the testicular sperm production rate.
Statistical analyses were conducted using SAS (21) statistical programs. Male body weight was analyzed by repeated measures analysis of variance, followed by one-way analysis of variance on individual days. Significant effects (P < 0.05) were pursued with the Tukey Studentized test. Organ weight data, age at balanopreputial separation, sperm production rate, epididymal sperm number, and numbers of corpora lutea, implants, and live embryos were analyzed by one-way analysis of variance followed by the Tukey Studentized test when significant analysis of variance results were obtained. Mating and fertility indices were analyzed by the chi-square test and Fisher's exact one-tail test. The percentage of preimplant loss and the early, late, and total postimplantation death rates were transformed by a binomial arcsine square-root transformation and analyzed by the KruskalWallis test followed by the Wilcoxon two-sample test. The litter was used as the unit of analysis for all cesarean delivery data.
RESULTS
Observations on juvenile males (6 to 37 days old). No animal died during the study in any treatment group. Body weight increased slightly in the majority of the antibiotic- Table 1 ). In mating trial 1 with moxalactamtreated rats, the mating index was significantly depressed in the group given 500 mg/kg per day, as was the fertility index in the groups given 500 and 1,000 mg/kg per day. In mating trial 2, the mating index remained low but was not statistically different from those of the controls in the groups given 500 and 1,000 mg/kg per day, while the fertility index was statistically smaller in both groups. There were no adverse effects on mating or fertility in the cephalothin or cefonicid treatment groups.
Untreated females impregnated by moxalactam-treated males in mating trial 1 had alterations in cesarean delivery parameters indicative of male subfertility (Table 2 ). There were dose-related decreases in the numbers of implants and live embryos and marked increases in the percentage of preimplantation loss. The results were significantly different in the group given 1,000 mg/kg per day. There were no significant differences in the percentage of postimplantation deaths, although this value was elevated in the group given 1,000 mg/kg per day of moxalactam (13.4 versus 5.3% for the control group).
In mating trial 2, there were no significant differences in cesarean delivery data from untreated females impregnated by moxalactam-treated males (data not shown). Dose trends persisted in the decreased numbers of implants and live embryos and increased preimplantation loss, but were not of sufficient magnitude to achieve statistical significance. Untreated females mated with cephalothin-treated males had slight but statistically significant decreases in the numbers of implants and live embryos in mating trial 1. In mating trial 2, the cesarean delivery data were comparable to those of the control group. There were no biologically or statisti- cally significant differences in cesarean delivery data from untreated females bred to cefonicid-treated males.
At autopsy of 102-day-old males, significant decreases in cauda epididymal weights were obtained after moxalactam treatment at 500 and 1,000 mg/kg per day. Testicular and ventral prostate weights remained depressed 500 mg/kg per day, but differences from the control group were not statistically significant. There were no significant decreases in reproductive organ weights in males treated with cephalothin or cefonicid (data not shown).
Histological examination was conducted on the left testis and cauda epididymis, ventral prostate, and seminal vesicle of each rat at 102 days of age. Control rats had typical spermatogenic activity characteristic of normal adult males. All stages of spermatogenesis were represented in the seminiferous tubules (Fig. 4A) , and epididymal tubules were filled with sperm. Treatment-related microscopic changes were observed in the left testis and cauda epididymis of each rat at all moxalactam doses. These changes were characterized by multifocal atrophy, in which foci of atrophic seminiferous tubules were scattered throughout the testis, or by diffuse atrophy, in which all of the seminiferous tubules were affected (Fig. 4B) . Diffuse atrophy was often accompanied by interstitial cell hyperplasia. The cauda epididymis of rats with multifocal or diffuse testicular atrophy contained fewer sperm and had necrotic spermatogenic cells in the lumen. All rats in the groups given 500 and 1,000 mg/kg per day of moxalactam had multifocal or diffuse testicular atrophy, while half in the group given 100 mg/kg per day had multifocal testicular atrophy. The findings with the moxalactam-treated 102-day-old rats were consistent with the changes seen in 37-day-old rats, but the severity and extent of involvement were greater at 102 days.
Histological examination of the left testis from each of 12 rats from the groups given cefonicid showed one occurrence of diffuse atrophy of the seminiferous tubules (rat 186, 250 mg/kg per day) or multifocal necrosis of the spermatogenic cells in several seminiferous tubules (rat 138, 50 mg/kg per day). Accompanying these testicular lesions were fewer sperm and the presence of necrotic spermatogenic cells in the lumen of the epididymal tubules. No microscopic changes were observed in the testes or epididymides in the remaining 11 males in each of these groups or in any males given 100, 500, or 1,000 mg/kg per day of cefonicid. Likewise, no treatment-related microscopic changes were observed in the reproductive organs of any rats treated with cephalothin.
Moxalactam-treated rats had decreased testicular sperm production rates and epididymal sperm numbers (Fig. 5) . Rats given 100 mg/kg per day had sperm production rates and epididymal sperm numbers slightly higher than those in controls, while those in the groups given 500 and 1,000 mg/kg per day had significant decreases in testicular sperm production rates or epididymal sperm numbers or both. Cephalothin or cefonicid treatment had no adverse effect on testicular sperm production rates or cauda epididymal sperm counts.
Samples of sera obtained at the 102-day autopsy were also evaluated for testosterone levels. There were no statistically significant differences in testosterone levels in serum in any treated group compared with levels in the control group (data not shown). All group averages were within the normal range for adult male rats (1.0 to 3.0 ng/ml) (10).
DISCUSSION
Disruption of sexual differentiation with moxalactam treatment was first evident in males at 37 days of age. Testicular or seminal vesicle weights or both were lower in the groups given 500 and 1,000 mg/kg per day, and histological examination of the testes revealed bilateral multifocal atrophy of the seminiferous tubules. Histological lesions of the testes were observed at all of the doses tested, including the low dose of 100 mg/kg per day.
Despite discontinuation of treatment at 37 days of age, moxalactam-treated males in the groups given 500 and 1,000 mg/kg per day were subfertile at 82 days of age. Some failed to mate, but the major effect-was on fertility, in that some females inseminated by moxalactam-treated males did not become pregnant. Those females that were impregnated by moxalactam-treated males had a marked elevation in preimplantation loss, with concomitant decreases in the numbers of implants and live embryos. These effects on the outcome of pregnancy can be attributed to a low sperm count, although effects on sperm motility cannot be discounted.
At autopsy, adult males treated with moxalactam had significant reductions in cauda epididymal weights and sperm counts in the groups given 500 and 1,000 mg/kg per day. While testicular weight was not significantly depressed, there were marked depressions in testicular sperm production rates. Histological examination of the contralateral testis revealed multifocal or diffuse atrophy of seminiferous tubules or both effects in all of the moxalactam treatment groups. The severity and extent of involvement were greater in males at 102 days of age than at 37 days of age.
Single occurrences of multifocal or diffuse atrophy of seminiferous tubules were seen in two rats, one each in the groups given 50 or 250 mg/kg per day of cefonicid. These same rats were found to have decreased spermatogenesis in all other measures of reproductive toxicity carried out in this study. They were infertile in mating trials, had reduced testicular and cauda epididymal weights, and had depressed sperm production rates and epididymal sperm counts. The incidence of rats with deficits in spermatogenic parameters in the groups given 50 and 250 mg/kg per day (1 of 12 [8%]) was not dose related and is within the historical control range for rats used in our laboratory. Approximately 1 of 15 male rats has been found to be spontaneously oligospermic with testicular sperm production rates lower than the 4 x 106 rate in the control data base. Consequently, it is likely that the deficits in the spermatogenic parameters of the two males (rats 138 and 186) were isolated spontaneous occurrences not related to cefonicid treatment.
The findings obtained in this study with the positive control, moxalactam, and with the negative control, cephalothin, are in agreement with previously published information (14) . Cephalosporin antibiotics containing the MTT side chain cause testicular atrophy in prepubertal rats, while those lacking the MTT side chain do not have this effect. Cefonicid, which contains a modified MTT side chain, had no adverse effects on the male reproductive system of prepubertal, juvenile, or adult rats when given under identical conditions. The lack of effect from cefonicid may be due to the inability of the modified side chain to interact with critical receptors or sites involved in sexual differentiation or to the ease with which the modified MTT group leaves the parent molecule.
There have been no published reports of testicular abnormalities in humans as a result of treatment with MTTcontaining antibiotics. It is not likely, however, that the reproductive effects would be manifested in exposed infants and children until postpubertal life. The maximum dose of moxalactam recommended for treatment of pediatric meningitis is 200 mg/kg per day (18) , and in this study, histological lesions in the testes were observed in 50% of the rats treated with 100 mg/kg per day at 37 and 102 days of age.
Therefore, it must be questioned whether human infants have the same susceptibility as juvenile rats to the testicular toxicity of MTT-containing antibiotics. Unfortunately, not enough is known about the mechanism of action to address this question. A key observation, however, is that the susceptible period for MTT extends from birth to the first 2 weeks of life (14) . This is a period in which sexual differentiation of the hypothalamic-pituitary-gonadal axis occurs in rodents. During this time, gonadal steroids have an imprinting effect at the hypothalamic-pituitary level that governs sexually differentiated neuroendocrine functions and reproductive behavior (11). Brief disturbances of the hormonal milieu during this period can result in permanent structural and functional changes in the reproductive system. Pharmacological levels of androgens or estrogens, as well as the 996 MANSON ET AL. (4) .
Furthermore, there appear to be major differences between rodents and primates in the timing of sexual differentiation of the central nervous system (8) . Rodents exhibit the greatest sensitivity to agents that disrupt sexual differentiation of the central nervous system during the first 2 weeks of life. Primates, however, appear to be most susceptible during the prenatal period, during which exposures to androgens and estrogens have caused permanent alterations in primate gonadal structure and reproductive behaviors.
Antibiotics containing the MTT side chain, as well as the side chain itself, have consistently been shown to disrupt sexual differentiation in the neonatal rat. Not enough information is available, however, to extrapolate these findings from immature rodents to human infants. UJntil more information is available, the risk of this side effect should be weighed against the benefit of administering MTT-containing antibiotics to humans in prenatal and prepubertal stages of life.
